Sight Sciences gets Buy rating with 70% upside on glaucoma and reimbursement tailwinds
H.C. Wainwright launched coverage on Sight Sciences with a Buy rating and a $14 price target, signaling a potential near-term re-rating of SGHT on its glaucoma and dry-eye platforms. Growth drivers include the OMNI glaucoma system and TearCare, plus broader reimbursement from Aetna, alongside improving sales efficiency. Risks remain from reimbursement variability and ongoing losses, but 2026–27 revenue growth targets provide a constructive path to profitability.
View signal analysis